BioMarin Pharmaceutical Inc. Stock News

BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.

The recent Japan approval of Voxzogo for achondroplasia would generate a leaping sales growth in the coming quarters. BioMarin is also expanding Voxzogo's label for younger kids afflicted by achondrop

SAN RAFAEL, Calif. , July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host

Upgrades For The Shyft Group Inc (NASDAQ:SHYF), DA Davidson upgraded the previous rating of Neutral to Buy. Shyft Group earned $0.06 in the first quarter, compared to $0.36 in the year-ago quarter. Th

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

When every rally attempt fails, like the two we have seen this week, market veterans know that it is likely that the path of least resistance for the stock market is lower, at least in the meantime.

On Friday, BioMarin Pharmaceutical received a positive CHMP opinion in Europe for ValRox for Hemophilia type A treatment. According to the last report, the core portfolio looks solid.

BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.

BioMarin (BMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BioMarin (BMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The top 3 positions are T-Mobile US, Amazon.com, and General Electric, together, at ~16% of the portfolio.